A prospective trial of sustained-release bupropion for depression in HIV-seropositive and AIDS patients

M. Beatriz Currier, German Molina, Martha Kato

Research output: Contribution to journalArticle

30 Scopus citations


To date, the authors know of no prospective studies of sustained-release bupropion in depressed HIV-seropositive patients. The purpose of this study was to evaluate the efficacy and tolerability of sustained-release bupropion in 20 depressed HIV-positive adult outpatients. Twenty outpatients with HIV spectrum illness, a DSM-IV-diagnosed major depressive disorder confirmed with the Structured Clinical Interview for DSM-IV, and Mini-Mental State Examination scores >20 were recruited into a 6-week, open-label, flexible-dose study of sustained-release bupropion (100-300 mg/day). Twelve patients (60%) responded to sustained-release bupropion at a mean dose of 265 mg/day. Five patients (25%) discontinued study participation secondary to adverse events. Preliminary findings suggest that sustained-release bupropion is effective for the treatment of depression in HIV-positive patients, regardless of HIV clinical staging. Furthermore, it appears to be well tolerated in patients with AIDS-related medical conditions.

Original languageEnglish
Pages (from-to)120-125
Number of pages6
Issue number2
StatePublished - Mar 1 2003
Externally publishedYes


ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Psychology(all)

Cite this